

Mark E Burkard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4414266/publications.pdf>

Version: 2024-02-01

81
papers

4,245
citations

201385

27
h-index

118652

62
g-index

85
all docs

85
docs citations

85
times ranked

5114
citing authors

#	ARTICLE	IF	CITATIONS
1	Thermodynamic Parameters for an Expanded Nearest-Neighbor Model for Formation of RNA Duplexes with Watson-Crick Base Pairs. <i>Biochemistry</i> , 1998, 37, 14719-14735.	1.2	1,055
2	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	13.9	454
3	Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles. <i>Science Translational Medicine</i> , 2014, 6, 229ra43.	5.8	298
4	Predicting oligonucleotide affinity to nucleic acid targets. <i>Rna</i> , 1999, 5, 1458-1469.	1.6	228
5	Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4383-4388.	3.3	228
6	Plk1 Self-Organization and Priming Phosphorylation of HsCYK-4 at the Spindle Midzone Regulate the Onset of Division in Human Cells. <i>PLoS Biology</i> , 2009, 7, e1000111.	2.6	170
7	Thermodynamics of Single Mismatches in RNA Duplexes. <i>Biochemistry</i> , 1999, 38, 14214-14223.	1.2	166
8	Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. <i>Clinical Cancer Research</i> , 2019, 25, 5376-5387.	3.2	145
9	Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. <i>BMC Cancer</i> , 2016, 16, 47.	1.1	89
10	Thermodynamics of unpaired terminal nucleotides on short RNA helices correlates with stacking at helix termini in larger RNAs. <i>Journal of Molecular Biology</i> , 1999, 290, 967-982.	2.0	79
11	Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 553.	1.3	74
12	PP2A-B α holoenzyme substrate recognition, regulation and role in cytokinesis. <i>Cell Discovery</i> , 2017, 3, 17027.	3.1	68
13	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	3.2	66
14	NMR Structures of r(GCAGGCGUGC) ₂ and Determinants of Stability for Single Guanosine-Guanosine Base Pairs. <i>Biochemistry</i> , 2000, 39, 11748-11762.	1.2	61
15	Visualization of Sequential Treatments in Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2020, 3, 1-8.	1.0	57
16	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3171-3181.	0.8	54
17	Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. <i>Science Translational Medicine</i> , 2021, 13, eabd4811.	5.8	48
18	High Mitotic Activity of Polo-like Kinase 1 Is Required for Chromosome Segregation and Genomic Integrity in Human Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 42812-42825.	1.6	46

#	ARTICLE	IF	CITATIONS
19	Behavior of Bubbles of Slowly Permeating Gas Used for Ultrasonic Imaging Contrast. <i>Investigative Radiology</i> , 1995, 30, 315-321.	3.5	44
20	Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. <i>Molecular Cancer Research</i> , 2018, 16, 517-527.	1.5	43
21	Decoding Polo-like kinase 1 signaling along the kinetochore-centromere axis. <i>Nature Chemical Biology</i> , 2016, 12, 411-418.	3.9	40
22	Simulation of exchanges of multiple gases in bubbles in the body. <i>Respiration Physiology</i> , 1994, 95, 131-145.	2.8	39
23	Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2659-2667.	3.2	39
24	Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2553-2567.	1.9	35
25	Update on Adjuvant Chemotherapy for Early Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2014, 8, BCBCR.S9454.	0.6	33
26	The energetics of small internal loops in RNA. <i>Biopolymers</i> , 1999, 52, 157-167.	1.2	31
27	Enabling and Disabling Polo-like Kinase 1 Inhibition through Chemical Genetics. <i>ACS Chemical Biology</i> , 2012, 7, 978-981.	1.6	31
28	Anillin Phosphorylation Controls Timely Membrane Association and Successful Cytokinesis. <i>PLoS Genetics</i> , 2017, 13, e1006511.	1.5	29
29	Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 48-59.	1.9	25
30	Interphase cytofission maintains genomic integrity of human cells after failed cytokinesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13026-13031.	3.3	24
31	MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 346-355.	1.9	24
32	Thermodynamics of RNA Internal Loops with a Guanosine-Guanosine Pair Adjacent to Another Noncanonical Pair. <i>Biochemistry</i> , 2001, 40, 2478-2483.	1.2	23
33	Centralspindlin assembly and 2 phosphorylations on MgcRacGAP by Polo-like kinase 1 initiate Ect2 binding in early cytokinesis. <i>Cell Cycle</i> , 2014, 13, 2952-2961.	1.3	19
34	Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. <i>Clinical Breast Cancer</i> , 2016, 16, 256-261.	1.1	19
35	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	18
36	Polo-like kinase 4 maintains centriolar satellite integrity by phosphorylation of centrosomal protein 131 (CEP131). <i>Journal of Biological Chemistry</i> , 2019, 294, 6531-6549.	1.6	18

#	ARTICLE	IF	CITATIONS
37	High Oxygen Partial Pressure in Tissue Delivered by Stabilized Microbubbles. <i>Advances in Experimental Medicine and Biology</i> , 1997, 411, 395-401.	0.8	18
38	Plk1 protects kinetochore centromere architecture against microtubule pulling forces. <i>EMBO Reports</i> , 2019, 20, e48711.	2.0	18
39	High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability. <i>BMC Cancer</i> , 2021, 21, 186.	1.1	16
40	Sheared Anti-AntiBase Pairs in a Destabilizing 2 Å–2 Internal Loop: The NMR Structure of 5'-(rGGCAAGCCU)2'. <i>Biochemistry</i> , 2002, 41, 14969-14977.	1.2	15
41	Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 713-721.	1.1	15
42	Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. <i>JCO Precision Oncology</i> , 2021, 5, 1312-1324.	1.5	15
43	Quantifying chromosomal instability from intratumoral karyotype diversity using agent-based modeling and Bayesian inference. <i>ELife</i> , 2022, 11, .	2.8	14
44	Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. <i>Journal of Oncology Practice</i> , 2017, 13, e486-e495.	2.5	12
45	A physician-scientist preceptorship in clinical and translational research enhances training and mentorship. <i>BMC Medical Education</i> , 2019, 19, 89.	1.0	12
46	Tuning Chromosomal Instability to Optimize Tumor Fitness. <i>Cancer Discovery</i> , 2017, 7, 134-136.	7.7	11
47	Centrosome Amplification in Cancer Disrupts Autophagy and Sensitizes to Autophagy Inhibition. <i>Molecular Cancer Research</i> , 2020, 18, 33-45.	1.5	11
48	Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer. <i>Molecular Oncology</i> , 2020, 14, 1898-1909.	2.1	11
49	Molecular Recognition in Purine-Rich Internal Loops: Thermodynamic, Structural, and Dynamic Consequences of Purine for Adenine Substitutions in 5'-(rGGCAAGCCU)2'. <i>Biochemistry</i> , 2002, 41, 14978-14987.	1.2	10
50	Polo Kinase and Cytokinesis Initiation in Mammalian Cells: Harnessing the Awesome Power of Chemical Genetics. <i>Cell Cycle</i> , 2007, 6, 1713-1717.	1.3	10
51	The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. <i>PLoS ONE</i> , 2016, 11, e0150225.	1.1	10
52	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. <i>Investigational New Drugs</i> , 2017, 35, 87-94.	1.2	9
53	Photosensitive lichenoid skin reaction to capecitabine. <i>BMC Cancer</i> , 2017, 17, 866.	1.1	9
54	CHARTS: a web application for characterizing and comparing tumor subpopulations in publicly available single-cell RNA-seq data sets. <i>BMC Bioinformatics</i> , 2021, 22, 83.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, <i>HER2</i> -mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1028-1028.	0.8	9
56	Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study. <i>Clinical Breast Cancer</i> , 2014, 14, 205-211.	1.1	8
57	Chromosomal instability upregulates interferon in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 627-638.	1.5	8
58	Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e433-e438.	1.1	8
59	Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome. <i>Clinical Breast Cancer</i> , 2017, 17, e151-e153.	1.1	7
60	MACROD2, an Original Cause of CIN?. <i>Cancer Discovery</i> , 2018, 8, 921-923.	7.7	7
61	Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 500-513.	1.0	7
62	Validating cancer drug targets through chemical genetics. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 251-257.	3.3	6
63	A randomized trial of immediate versus delayed survivorship care plan receipt on patient satisfaction and knowledge of diagnosis and treatment. <i>Cancer</i> , 2019, 125, 1000-1007.	2.0	6
64	Analysis of the <i>centrosome-ome</i> identifies MCPH1 deletion as a cause of centrosome amplification in human cancer. <i>Scientific Reports</i> , 2020, 10, 11921.	1.6	5
65	Centriole and Golgi microtubule nucleation are dispensable for the migration of human neutrophil-like cells. <i>Molecular Biology of the Cell</i> , 2021, 32, 1545-1556.	0.9	5
66	Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 292-301.	1.1	4
67	Integrating the <i>NCI</i> Data with <i>Omic</i> s for Drug Discovery. <i>Drug Development Research</i> , 2012, 73, 420-429.	1.4	3
68	The Final Link: Tapping the Power of Chemical Genetics to Connect the Molecular and Biologic Functions of Mitotic Protein Kinases. <i>Molecules</i> , 2012, 17, 12172-12186.	1.7	3
69	Aromatase inhibitors and calcium absorption in early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 245-251.	1.1	3
70	<i>TRIMing</i> the Patient Population to Increase the Benefit of mTOR Inhibition. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	2
71	Breast cancer immunotherapy: Current biomarkers and the potential of <i>in vitro</i> assays. <i>Current Opinion in Biomedical Engineering</i> , 2022, 21, 100348.	1.8	2
72	A Genetic Toggle for Chemical Control of Individual Plk1 Substrates. <i>Cell Chemical Biology</i> , 2020, 27, 350-362.e8.	2.5	1

#	ARTICLE	IF	CITATIONS
73	Prospective study of work limitations in cancer patients (pts) undergoing curative chemotherapy (CT).. Journal of Clinical Oncology, 2017, 35, 18-18.	0.8	1
74	Classes of therapeutics to amplify the immune response. Breast Cancer Research and Treatment, 2022, 191, 277-289.	1.1	1
75	In the interest of full disclosure. Lancet Oncology, The, 2010, 11, 314-315.	5.1	0
76	Genomic instability and carcinogenesis. , 0, , 93-112.		0
77	Using cancer genomics to guide clinical decisions. Cancer, 2017, 123, 1288-1291.	2.0	0
78	Abstract 2986: Partial inhibition of Plk1 is cytotoxic despite normal spindle structure. , 2011, , .		0
79	Abstract 2638: Novel synergy of radiosensitizer prodrug IPdR with Aurora kinase inhibitors in triple-negative breast cancer. , 2014, , .		0
80	Centrosome amplification and prognosis in breast cancer.. Journal of Clinical Oncology, 2015, 33, 11036-11036.	0.8	0
81	Shared Knowledge in Precision Cancer Care. Wisconsin Medical Journal, 2018, 117, 178-179.	0.3	0